Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

ass="discStyle" type="disc">
  • Patents relating to capsaicin prodrugs entitled, "TRPV1 Agonist Compounds and Methods for Making and Using the Same," have issued in the United Stated and Mexico.

    • Patents relating to capsaicin oils entitled, "Oils of Capsaicinoids and Methods of Making and Using the Same," have issued in the United States, throughout Europe and Eurasia.

    • With respect to the skin cleansing gel, which is a component of the Qutenza treatment kit and is used to remove residual capsaicin from the skin after a Qutenza treatment, patents entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces," have issued in Eurasia and Japan.  

    • A patent relating to a capsaicin patch including specific penetration enhancers entitled, "Device for Delivery of TRPV1 Agonists," has issued in South Africa.

    About NeurogesX, Inc.

    NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

    The Company's lead product, Qutenza®, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza&#
    '/>"/>

    SOURCE NeurogesX
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
    5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
    6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
    7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
    8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
    9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
    10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
    11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
    (Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
    (Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, 2014 ... and Integrated Clinical Trial Services, LLC (ICTS), two ... clinical trials announce that they have formed a ... (i-CTMS). i-CTMS will provide a broad range of ... and medical device companies. i-CTMS will ...
    Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
    ... June 25 Perrigo Company (Nasdaq: PRGO ; TASE) announced ... present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference ... at the Four Seasons Hotel in Boston .  The presentation will ... , , ...
    ... 25 PartsSource, the world,s #1 ebusiness solution ... has been honored with the 2010 Manny Award for ... its 13th year, the Manny Award program is committed ... companies for their innovations and best practices. This was the ...
    Cached Medicine Technology:Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference 2PartsSource Wins 2010 Manny Award for Workplace Environment 2
    (Date:12/17/2014)... gas prices rose in recent years, so did motorcyclist ... times of gas increases, more people start using motorcycles ... explained. They examined data gathered between 2002 and ... motorcycle registrations in the United States and the third ... a strong association between rising gas prices and an ...
    (Date:12/17/2014)... participation in music classes may benefit children,s language development, ... the nonprofit Harmony Project, which provides music education and ... two years, children who actively participated in the classes ... and reading, compared to those with lower levels of ... music classes occurred in the same areas of the ...
    (Date:12/15/2014)... 2014 A recent survey found that ... as impacting skin health and beauty were: “Connections,” “climate,” ... care.” Water and health advocate and radio host Sharon ... describing the survey and the Four C’s.* Kleyne notes, ... category discussed would benefit from paying attention to one’s ...
    (Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
    (Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
    Breaking Medicine News(10 mins):Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
    ... from early magnetic resonance imaging, according to the ... in Canada MRI technology could determine //if performing ... that trauma-induced spinal cord compression on MRIs predict ... spinal cord compression. However, unless surgeons are fairly ...
    ... condition that affects primarily women. The condition is characterized ... rest and often worsens with physical activity. The cause ... diagnostic tests or cures. A recent study explains that ... for developing chronic fatigue later in life. ,Researchers ...
    ... a connection between the use of two of the ... reduced risk for // bone fractures. Beta-blockers are commonly ... chest pain, and abnormal heart rhythms. Some heart attack ... attack. Diuretics are used to remove excess water from ...
    ... undertaken at Wake Forest University Baptist Medical Center researcher ... suggested //that the type of progestin in hormonal therapy ... ,At an annual meeting of the North American ... Williams who is the lead investigator from Wake Forest ...
    ... Retinitis pigmentosa, a progressive eye disease targeting the light-collecting ... worldwide and can cause // vision loss. Researchers say ... docosahexaenoic acid to vitamin A therapy may not provide ... followed 221 patients, ranging in age from 18 to ...
    ... Researchers have found that chemotherapy improves survival and reduces the ... // (cancer that has not spread beyond the ovary). ... confined to the ovaries, when five-year survival is 85 percent. ... patients, since eight in 10 patients are adequately treated by ...
    Cached Medicine News:Health News:Hormone therapy may affect heart attack severity in women 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: